The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 5, 2010, Pages 394-399

  Nicolini, Franck ^a,b   Chomel, Jean Claude ^b,c   Roy, Lydia ^b,d   Legros, Laurence ^b,e   Chabane, Kaddour ^f   Ducastelle, Sophie ^a   Nicolas Virelizier, Emmanuelle ^a   Michallet, Mauricette ^a,b   Tigaud, Isabelle ^e   Magaud, Jean Pierre ^f   Turhan, Ali ^b,c   Guilhot, François ^b,d   Hayette, Sandrine ^b,f  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b French intergroup for CML (Fi LMC group)   (France)

^c UNIVERSITÉ DE POITIERS   (France)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

BCR ABL; Homoharringtonine; Imatinib mesylate; Omacetaxine mepesuccinate

Indexed keywords

BCR ABL PROTEIN; CGX 202; DASATINIB; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; UNCLASSIFIED DRUG; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; HARRINGTONINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CHRONIC PHASE CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLONE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; INJECTION SITE PAIN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; DRUG ANTAGONISM; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 79952276567     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.073     Document Type: Article

References (21)

1. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first line treatment of chronic myeloid. Leukemia 2009; 23:1054-61.
2. Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukaemia: strategies to avoid and overcome resistance. Leukemia 2004; 18:1321-31. (Pubitemid 39136739)
3. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-80. (Pubitemid 32743979)
4. Nicolini FE, Corm S, Lê Q-H, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC group). Leukemia 2006; 20:1061-6. (Pubitemid 43797298)
5. Nicolini FE, Hayette S, Corm S, et al. Clinical outcome of 27 imatinib mesylate resistant chronic myelogenous leukemia patients harbouring a T315I BCR-ABL mutation. Haematologica 2007; 92:1238-41. (Pubitemid 350144183)
6. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006; 20:1767-73. (Pubitemid 44574988)
7. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia. Clin Cancer Res 2006; 12:7374-9. (Pubitemid 46095411)
8. Nicolini FE, Mauro MJ, Martinelli G, et al. Epidemiological study on survival of chronic myeloid leukemia (CML) and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood 2009; 114:5271-8.
9. Legros L, Hayette S, Nicolini FE, et al. BCR-ABLT315I transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: A new therapeutic challenge? Leukemia 2007; 21:2204-6. (Pubitemid 47423816)
10. de Lavallade H, Khorashad JS, Davis HP, et al. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood 2007; 110:2779-80. (Pubitemid 47523217)
11. O'Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995; 86:3322-6.
12. O'Brien S, Kantarjian H, Koller C, et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999; 93:4149-53. (Pubitemid 29279257)
13. Quintás-Cardama A, Kantarjian H, Garcia-Manero G, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007; 109:248-55. (Pubitemid 46106239)
14. Cortes-Franco J, Khoury HJ, Nicolini FE, et al. Safety and efficacy of subcutaneous-administered Omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the BCR-ABL T315I mutation-Results of an ongoing multicenter phase 2/3 study. Presented at: the 51st American Society of Hematology (ASH) Annual Meeting and Exposition; December 5-8, 2009; New Orleans, LA. Abstract 644.
15. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17:2318-57. (Pubitemid 38072573)
16. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108:28-37. (Pubitemid 43990609)
17. Chomel JC, Sorel N, Bonnet ML, et al. Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML). Leuk Res 2009; 33:551-5.
18. Hayette S, Michallet M, Baille M-L, et al. Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients. Leuk Res 2005; 29:1073-7. (Pubitemid 40982602)
19. Allan E, Jørgensen HJ, Michaels S, et al. Omacetaxine cytotoxic activity in chronic myeloid leukemia stem cells. Haematologica 2009; 94(suppl 2): (abstract 1052).
20. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21:926-35. (Pubitemid 46672068)
21. Jiang X, Saw KM, Eaves A, et al. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007; 99:680-93. (Pubitemid 47073530)